NASDAQ$ELVN
Enliven Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2020 and reviewed recent business highlights.
Imara Inc. reported its third quarter 2020 financial results, highlighting the ongoing Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia, as well as the Orphan Drug designation granted by the European Commission for sickle cell disease.
- Patient dosing is underway in Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia.
- The European Commission granted IMR-687 Orphan Drug designation for sickle cell disease.
- Dosing was completed in the Phase 2a clinical trial in patients with Sickle Cell Disease during the third quarter of 2020.
- Cash, cash equivalents and investments were $96.1 million as of September 30, 2020.
Headline financials
Revenue & EPS history
Enliven Therapeutics · Revenue · Quarterly
$0
Forward guidance
Imara Inc. provided financial guidance for the full year 2020 and expects that its cash, cash equivalents and investments as of September 30, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.4%
Avg return
30 days after
48%
11 / 23 earnings
Positive
+17.6%
Q2 2020
Best reaction
-22.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +4.3% | +3.4% | +35.1% | |
| Q3 2025 | -0.3% | +11.3% | -16.9% | |
| Q2 2025 | -0.8% | -1.1% | -0.1% | |
| Q1 2025 | +0.4% | +19.7% | +29.3% | |
| Q4 2024 | -3.5% | -7.7% | -14.6% | |
| Q3 2024 | -8.3% | -8.4% | -14.8% | |
| Q1 2024 | -2.0% | -5.9% | -10.1% | |
| Q4 2023 | -2.4% | +43.0% | +71.8% | |
| Q3 2023 | -9.3% | -12.4% | -4.5% | |
| Q2 2023 | -2.0% | -8.0% | -7.1% | |
| Q1 2023 | -2.4% | -0.3% | +8.8% | |
| Q4 2022 | +2.1% | +4.5% | +2.6% | |
| Q3 2022 | +0.4% | -5.5% | -1.3% | |
| Q2 2022 | +2.5% | -1.7% | -3.4% | |
| Q1 2022 | -6.1% | -11.5% | -12.2% | |
| Q4 2021 | +11.1% | +22.2% | -27.8% | |
| Q3 2021 | +0.8% | -3.8% | -20.2% | |
| Q2 2021 | +0.3% | -18.0% | -14.5% | |
| Q1 2021 | +12.8% | +15.8% | +27.3% | |
| Q4 2020 | -22.5% | -19.5% | -31.7% | |
| Q3 2020 | -3.4% | +13.9% | +57.0% | |
| Q2 2020 | +17.6% | +19.8% | +8.1% | |
| Q1 2020 | +1.1% | +4.4% | +108.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro